These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The transfusion of HLA-matched platelets to thrombocytopenic patients resistant to random donor platelets. Levy L; Woodfield DG N Z Med J; 1984 Oct; 97(766):719-21. PubMed ID: 6595558 [TBL] [Abstract][Full Text] [Related]
3. Disparate risks and effects of pooled whole blood-derived vs. apheresis platelet production require an integral view on the blood supply. Zimmermann R; Blasczyk R; Zingsem J; Eckstein R; Heuft HG Vox Sang; 2010 Oct; 99(3):295-6; author reply 297-8. PubMed ID: 20561324 [No Abstract] [Full Text] [Related]
5. Donor exposures in recipients of pooled platelet concentrates. Thiele T; Heddle N; Greinacher A N Engl J Med; 2013 Jan; 368(5):487-9. PubMed ID: 23363522 [No Abstract] [Full Text] [Related]
6. The ethics of wasting the donor's gift of buffy coat. Vamvakas EC Vox Sang; 2011 Feb; 100(2):256-7; author reply 258-9. PubMed ID: 20825600 [No Abstract] [Full Text] [Related]
7. [Transfusion of platelet concentrates]. Rieux C; Lee K; Lavaud A; Bierling P Ann Med Interne (Paris); 1999 Dec; 150(8):631-41. PubMed ID: 10686645 [TBL] [Abstract][Full Text] [Related]
8. [The need of a registry of HLA-phenotyped platelet donors]. Castro Izaguirre E; Muncunill Ribas J Med Clin (Barc); 1995 Nov; 105(18):696-9. PubMed ID: 8538251 [No Abstract] [Full Text] [Related]
9. The perils of platelet transfusions. Kruskall MS N Engl J Med; 1997 Dec; 337(26):1914-5. PubMed ID: 9407160 [No Abstract] [Full Text] [Related]
11. Diagnosis and management of refractoriness to platelet transfusion. Schiffer CA Blood Rev; 2001 Dec; 15(4):175-80. PubMed ID: 11792118 [TBL] [Abstract][Full Text] [Related]
12. Standardization of plateletpheresis products. Ciavarella DA Transfus Sci; 1993 Oct; 14(4):363. PubMed ID: 10146642 [No Abstract] [Full Text] [Related]
13. Alloimmunization by leukocyte-rich or leukocyte-poor random single donor platelets. Gmür J; Burger J; Sauter C; Oelz O; Frick PG Prog Clin Biol Res; 1990; 337():45-8. PubMed ID: 2191337 [No Abstract] [Full Text] [Related]
14. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004-2006). Eder AF; Kennedy JM; Dy BA; Notari EP; Weiss JW; Fang CT; Wagner S; Dodd RY; Benjamin RJ; Transfusion; 2007 Jul; 47(7):1134-42. PubMed ID: 17581147 [TBL] [Abstract][Full Text] [Related]
15. Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension. Claas FH; Smeenk RJ; Schmidt R; van Steenbrugge GJ; Eernisse JG Exp Hematol; 1981 Jan; 9(1):84-9. PubMed ID: 7238645 [TBL] [Abstract][Full Text] [Related]
16. Quality and safety of platelet apheresis concentrates produced with a new leukocyte reduction system. Riggert J; Humpe A; Simson G; Köhler M Vox Sang; 1998; 74(3):182-8. PubMed ID: 9595646 [TBL] [Abstract][Full Text] [Related]